At the Children’s Tumor Foundation, we’re obsessed with bettering the lives of the over 2.5 million people living with neurofibromatosis (NF). We want to end NF as fast as we can, by connecting the unconnected in novel and untraditional ways.

Our innovative approach attracts the brightest minds in research and industry to NF, revamps the systems that will accelerate the pathway from discovery to treatment, and includes the voice of the patient every step of the way.

Read about the incredibly important things that happened in 2019, which are even now laying the groundwork for even more critical approvals in the future.

**TOP TEN ADVANCEMENTS IN NF RESEARCH 2019**

1. Attracting fresh ideas and new energy to the NF space through the NF Data Hackathon. (ctf.org/2019hackathon)
2. Making all NF Data available so we can learn from each other. (ctf.org/2019data)
3. Telling the MEK story - speeding the path to approved treatments for NF. (ctf.org/2019MEK)
4. NF Innovation Week brings together world’s experts for knowledge sharing at the NF Conference. (ctf.org/2019conference)
5. Patients as Partners: NF Patient Advocates Speak Directly to the FDA for the first time. (ctf.org/2019patients)
6. Going Global: Developing new clinical trial platforms to bring treatments to patients, in partnership with EU-PEARL in Europe. (ctf.org/2019global)
7. Expanding NF knowledge through groundbreaking pig models that increase what we know about NF. (ctf.org/2019models)
8. Launching the NF2 Accelerator initiative to fuel the clinical pipeline and gene therapy. (ctf.org/nf2accelerator)
9. Changing the world for low grade glioma patients through Synodos. (ctf.org/2019LGG)
10. FDA accepts submission of selumetinib (MEK) as a potential approved treatment for NF and grants priority review. First time in NF history. (ctf.org/2019FDAPriority)

Stay informed with NF research updates throughout the year at ctf.org/news.

CHILDREN’S TUMOR FOUNDATION
370 Lexington Avenue Ste. 2100
New York, NY 10017
(800) 323-7938 • info@ctf.org
ctf.org